Aridis Pharmaceuticals (ARDS)
(Delayed Data from OTC)
$0.00 USD
-0.01 (-99.00%)
Updated Sep 5, 2024 02:38 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ARDS 0.00 -0.01(-99.00%)
Will ARDS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ARDS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARDS
Avid Bioservices (CDMO) Reports Q2 Loss, Lags Revenue Estimates
Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
ARDS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug
Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design
Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More
Other News for ARDS
Aridis Provides Corporate Update